The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Harry J.M. Groen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst)
Research Funding - Roche (Inst)
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Lilly/ImClone; PFIZER; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; boehringer ingelheim; Lilly/ImClone; pfizer; Roche/Genentech
Research Funding - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; LILLY (Inst); Novartis; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - LILLY; PFIZER
 
Elisabeth A. Quoix
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche
 
Christina S. Baik
Consulting or Advisory Role - Novartis
Research Funding - Celgene (Inst); Clovis Oncology (Inst); Incyte (Inst); Millennium (Inst); Novartis (Inst)
 
Fabrice Barlesi
Honoraria - Novartis
Consulting or Advisory Role - Novartis
 
Tae Min Kim
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly/ImClone; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Silvia Novello
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche
 
James R. Rigas
No Relationships to Disclose
 
Allison Upalawanna
Employment - Novartis
 
Anthony Michael D'amelio
Employment - GlaxoSmithKline; Novartis
Stock and Other Ownership Interests - GlaxoSmithKline
 
Pingkuan Zhang
Employment - GlaxoSmithKline; Novartis
 
Bijoyesh Mookerjee
Employment - GlaxoSmithKline; Novartis
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma; Merck
Consulting or Advisory Role - AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Genentech; KEW; Merck; Novartis; Otsuka; Puma Biotechnology; Teva; Transgene
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
Expert Testimony - Genentech